Ryuichi Onose is the CEO and Founder of Craif. He established the company in 2018 with the mission to end the war on cancer through data-driven, non-invasive diagnostics based on urinary microRNA analysis.
Before founding Craif, Ryuichi launched and scaled a nationwide vacation rental business while working full-time at Mitsubishi Corporation, where he managed LNG shipping projects importing shale gas from the U.S. to Japan.
He holds a bachelor’s degree from the School of International Liberal Studies at Waseda University and completed an exchange program at McGill University in Canada.
Ryuichi was named one of Forbes Asia’s 30 Under 30 in 2021.

Dr. Takao Yasui is a Professor at the School of Life Science and Technology, Tokyo University of Science, and serves as Craif’s Technical Advisor and Co-founder. He co-founded Craif in 2018 after pioneering a nanowire-based technology capable of detecting cancer from just 1 mL of urine—developed through his research on exosome quantification as cancer-related signaling factors. Prior to his current role, he served as Associate Professor at Nagoya University’s Graduate School of Engineering and as a researcher in JST’s PRESTO program. He was also Assistant Program Manager for the ImPACT program from 2014 to 2019. His research focuses on developing novel biomolecular analysis techniques using nanospaces.

Dr.Yuki Ichikawa is the Chief Technology Officer of Craif and a Visiting Associate Professor at Nagoya University’s Institute of Innovation for Future Society. He oversees the company’s technology strategy, platform development, and integration of omics analytics into clinically viable diagnostic tools.
With a Ph.D. in chemical biology from the University of Tokyo, Dr. Ichikawa brings a rare combination of deep academic expertise and cross-functional industry experience. Prior to Craif, he held strategic roles at Bayer, contributing to oncology and ophthalmology business lines as well as leading enterprise-level initiatives in corporate planning and transformation.
His background also includes global health innovation, where he supported the implementation of medical technologies in emerging markets through international non-profits.

Dr. Mika Mizunuma is Chief Operating Officer of Craif, where she leads enterprise operations, organizational scaling, and cross-functional execution. With a background spanning pharmaceutical R&D, strategic consulting, and digital health entrepreneurship, she plays a key role in advancing Craif’s global growth and operational excellence.
She began her career at AstraZeneca in Medical Affairs, focusing on the strategic launch of new therapeutics. She then joined McKinsey & Company, advising pharmaceutical and medtech clients on market entry, portfolio strategy, and organization design. In 2017, she founded a digital health startup offering AI-driven patient engagement solutions.
Dr. Mizunuma holds a Ph.D. in Pharmaceutical Sciences from the University of Tokyo and a bachelor’s degree from Kyoto University.

Keisuke Honda serves as an Outside Director of Craif, contributing his global entrepreneurial perspective and network to the company’s strategic initiatives. He is Co-Founder and General Partner of X&KSK, a venture capital firm with a mission to support Japan’s next-generation unicorns.
Internationally known as a professional footballer and coach, Mr. Honda has built a parallel career as an angel investor and social entrepreneur. He founded the KSK Angel Fund in 2016, co-founded the Dreamers Fund with actor Will Smith in 2018, and launched X&KSK in 2024 to back high-growth ventures with transformative potential.
He brings to Craif a unique combination of global leadership, investment acumen, and a bold vision for impact-driven innovation.